Evidence map›Paper›PMID 32792589›Full record

ArticleNature chemical biology2020

Publisher Correction: A mass spectrometry-based proteome map of drug action in lung cancer cell lines.

Benjamin Ruprecht, Julie Di Bernardo, Zhao Wang, Xuan Mo, Oleg Ursu, Matthew Christopher, Rafael B Fernandez, Li Zheng, Brian D Dill, Huijun Wang and 10 more

Abstract readPublished Erratum
PubMed Publisher
In one paragraph

Article in Nature chemical biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors.

Benjamin RuprechtChemical Biology, Merck, Boston, MA, USA. benjamin.ruprecht@merck.com.ORCID http://orcid.org/0000-0001-9807-5825
Julie Di BernardoChemical Biology, Merck, Boston, MA, USA.
Zhao WangChemical Biology, Merck, Boston, MA, USA.
Xuan MoChemical Biology, Merck, Boston, MA, USA.ORCID http://orcid.org/0000-0001-8638-6482
Oleg UrsuChemoinformatics, Merck, Boston, MA, USA.
Matthew ChristopherChemical Biology, Merck, Boston, MA, USA.
Rafael B FernandezPharmacology, Merck, Boston, MA, USA.
Li ZhengChemical Biology, Merck, Boston, MA, USA.
Brian D DillChemical Biology, Merck, Boston, MA, USA.ORCID http://orcid.org/0000-0002-4532-3044
Huijun WangChemoinformatics, Merck, Kenilworth, NJ, USA.
Yuting XuBiometrics Research, Merck, Rahway, NJ, USA.ORCID http://orcid.org/0000-0003-2091-3854
Andy LiawBiometrics Research, Merck, Rahway, NJ, USA.
Jonathan D MortisonChemical Biology, Merck, Boston, MA, USA.
Nirodhini SiriwardanaChemical Biology, Merck, Boston, MA, USA.
Brian AndresenChemical Biology, Merck, Boston, MA, USA.
Meir GlickChemoinformatics, Merck, Boston, MA, USA.
James R TataChemical Biology, Merck, Kenilworth, NJ, USA.
Victoria KutilekChemical Biology, Merck, Boston, MA, USA.
Ivan Cornella-TaracidoChemical Biology, Merck, Boston, MA, USA.
An ChiChemical Biology, Merck, Boston, MA, USA. an_chi@merck.com.ORCID http://orcid.org/0000-0002-8213-1826

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Identifiers

PMID32792589

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.